UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of the earliest event reported): May 5, 2009
Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
1-11397
|
|
33-0628076 |
| (State or other jurisdiction of
|
|
(Commission File Number)
|
|
(I.R.S Employer |
| incorporation or organization)
|
|
|
|
Identification No.) |
One Enterprise
Aliso Viejo, California 92656
(Address of principal executive offices) (Zip Code)
(949) 461-6000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 2.02 Results of Operations and Financial Condition
Valeant
Pharmaceuticals International (the “Company”) furnished a
Current Report on Form 8-K on
May 5, 2009 (the “Original Form 8-K”) announcing the Company’s results of operations for the
quarter ended March 31, 2009 and certain other financial information as of and for the quarter
ended March 31, 2009.
This Amendment No. 1 on Form 8-K/A (this “Amended Form 8-K”) is being furnished to amend the
Original Form 8-K to reflect a revised classification between cash flow from operating activities
in continuing operations and cash flow from financing activities relating to the quarter ended
March 31, 2009. This revised classification (required by FSP APB 14-1) relates to $13,277,000 of
payments of accreted interest on long-term debt and notes payable made during the quarter. As a
result, the cash flow generated from operating activities in continuing operations for such period
was reduced by $13,277,000 to $37,822,000 and cash out flow from financing activities for such
period was decreased by the same $13,277,000 to $43,737,000. The net decrease in cash and
marketable securities for such period remains unchanged at $72,936,000. The information furnished
in this Amended Form 8-K, including the information furnished in Exhibit 99.1 hereto, amends and
supersedes the information furnished by the Original Form 8-K, including the information provided
under the caption “Other Data” in Table 5 to the press release furnished by the Original Form 8-K.
The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be
deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and
Exhibit 99.1 shall not be incorporated by reference into any registration statement or other
document pursuant to the Securities Act of 1933, as amended.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Updated Cash Flow Data.